What Is BPC-157? Pentadecapeptide Structure, Proposed Mechanisms and Evidence Limits

BPC-157 is a synthetic peptide of fifteen amino acids — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — described in publications as a stable fragment of a protein found in human gastric juice. It is simultaneously the most extensively studied tissue-repair research peptide and one of the most commonly oversold, so this page draws a clear line between what the published work actually reports and what it does not. Our research-grade BPC-157 comes as lyophilized powder in sealed vials, for laboratory use only.

BPC-157 defined

The abbreviation BPC means body protection compound. The molecule is a 15-residue stretch taken from a larger protein reported in gastric juice, and its most notable practical feature is durability: unlike most short peptides it is described as resisting degradation in human gastric juice for hours — unusual behaviour, and the reason oral and mucosal presentations of it exist at all. The term pentadecapeptide simply denotes its fifteen residues.

One caveat belongs on any technically honest page. The parent protein said to give rise to BPC-157 is not well documented in mainstream proteomics research, and no endogenous receptor for the peptide has been confirmed. The accurate description is a synthetic sequence with reported biological activity — not a well-characterised fragment of a known signalling system.

Origin and structure

• Sequence. Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val: fifteen residues, linear, with no disulfide bonds.
• Makeup. It has four prolines and no cysteine, methionine or aromatic residues. The proline content limits conformational freedom and helps explain its resistance to proteases; the lack of methionine removes a common oxidation liability; and without tryptophan or tyrosine it absorbs almost no UV at 280 nm, so analysis depends on peptide-bond absorbance near 214 nm.
• Identifiers. CAS 137525-51-0, formula C62H98N16O22, molecular weight 1419.55 Da.
• Salt form. Usually supplied as the acetate salt; arginate-salt material also circulates, and in terms of what a weighed sample actually contains these are different substances.

Proposed mechanisms of action

No specific receptor has been identified, and that absence colours every description of its mechanism. Rather than one pathway, the literature proposes several that converge:

• Angiogenesis. The most consistently reported theme, with studies describing increased VEGF receptor 2 signalling and greater vessel formation in angiogenesis assays and tissue models.
• Involvement of the nitric oxide system. Several papers report effects that change in the presence of NO synthase inhibitors or NO donors, implicating that pathway.
• Effects on growth factors and fibroblasts. Reported influences on fibroblast migration, collagen organisation and FAK-paxillin signalling in cells derived from tendon.
• Gut-brain axis and neurotransmitters. A smaller body of work reports interactions with dopaminergic and serotonergic systems, mostly from one research group.

That last observation applies more broadly. A large proportion of the BPC-157 literature comes from a single group in Croatia. This is no reason to dismiss the work, but it is a strong reason to give independent replication particular weight where it exists. Our review of what BPC-157 has and has not been studied for examines this in depth.

Research applications

• Gastrointestinal models. The original field: rodent models of gastric and intestinal mucosal damage, inflammatory bowel models and fistula healing.
• Tendon, ligament and muscle. Rodent transection and injury models reporting faster tissue recovery, together with cell studies on tendon fibroblast migration.
• Vascular and organ studies. Research on vessel formation and reports from models of organ injury.
• Human data. Substantial published human trial evidence does not exist. Some early-phase work has been registered, but peer-reviewed human outcome data are effectively absent. Every familiar claim about this peptide comes from rodent and cell experiments.

Before building anything on this literature, it helps to understand the methodological pattern in the rodent studies. Most apply an acute injury model — a transection, an induced lesion, a chemically provoked mucosal defect — and then compare treated and control tissue at a set endpoint. Such designs are good at detecting acceleration of repair already under way, and they suit the question those papers posed. They say considerably less about a system that is not actively repairing, which is precisely the context most extrapolations assume. So when evaluating a claim about BPC-157, ask first which model generated it and whether that model resembles the situation being extrapolated to.

Available formats

Besides injectable vials, BPC-157 is offered as capsules, sublingual troches, nasal spray and cream, along with blends such as BPC-157 with TB-500 and BPC-157 with KPV. Its exceptional gastric stability is what makes the oral presentations credible in the first place. All of it belongs to the tissue repair peptides collection.

A word about administration route in preclinical studies. Published rodent work has used intraperitoneal, intragastric and topical routes, and reported effects differ between them. Because the peptide is described as gastric-stable, intragastric studies are unusually well represented for a peptide this size, and several papers compare routes directly. So cite the route along with the effect: a result obtained after intragastric administration is not evidence of the same result by a different route, and blurring that distinction is among the most frequent mistakes in secondary summaries of this literature — one that spreads rapidly once a claim leaves the original paper.

Reconstitution and storage at the bench

The calculation is a bench exercise: 2 mL of bacteriostatic water in a 10 mg vial gives 5 mg/mL (5,000 mcg/mL), so 0.1 mL of that solution holds 500 mcg of peptide. BPC-157 is easy to prepare — small, water-soluble, without disulfide bonds or oxidation-prone residues — which is part of why laboratories new to peptide work often start with it.

Keep sealed lyophilized powder at minus 20 degrees Celsius, away from light and moisture; store reconstituted solution at 2 to 8 degrees Celsius and use it within the study period. Aliquot at reconstitution to avoid repeated freeze-thaw cycles. See our reconstitution guide.

Purity and reading the certificate of analysis

A certificate should show an HPLC chromatogram with main-peak area percentage, mass-spectrometric identity against the theoretical 1419.55 Da, net peptide content, lot number and analysis date. Two points apply specifically to BPC-157. First, salt form: acetate and arginate salts differ in peptide content per milligram, so a certificate omitting both salt form and net peptide content leaves the true concentration of your solution unknown. Second, detection wavelength: lacking aromatic residues, this peptide is measured at about 214 nm, and a chromatogram recorded only at 280 nm would show virtually nothing — a useful clue as to whether a certificate was genuinely produced for this molecule or copied from a template. See how to read a COA.

Two further considerations shape how this peptide should be treated as a research object. One is analytical: with four prolines and no aromatic residues, BPC-157 produces an unexceptional chromatogram, and deletion sequences lacking a single proline elute close to the main peak. A high purity value from a short gradient is therefore weaker evidence than the same value from a gradient that separates those neighbours — the method matters as much as the figure. The other is evidential: since so much secondary writing condenses rodent findings into sweeping claims, any laboratory citing this peptide should go back to the primary papers and note species, model, route and endpoint. It costs little time and is what separates a defensible statement about observed results from the repetition of a claim that has lost its original scope.

Regulatory position

BPC-157 is not an approved medicine in any country. In the United States the FDA has placed it in the category of bulk substances ineligible for compounding — a specific regulatory determination, not a safety judgement either way. It also appears on the World Anti-Doping Agency prohibited list. Research-grade BPC-157 is supplied as a laboratory reference chemical for research use only, not for human consumption.

Related compounds and comparisons

The pairing asked about most often is with TB-500, covered in BPC-157 vs TB-500.